Contact Us

Focus

Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075,a once-daily oral GLP-1RA,reporting 5% placebo-adjusted weight-loss with no plateau

Focus

Jan 13, 2025

2024 Marks Breakout Year for China's ETF Market with Unprecedented Growth

GUANGZHOU,China,Jan. 10,2025--China\'s ETF market demonstrated exceptional performance in 2024,with notable returns and substantial growth in assets under management. According to Wind,the average re

Focus

Jan 13, 2025

Agoda's 2025 Travel Calendar: A Month-by-Month Guide to Asia

SINGAPORE,Jan. 13,2025-- Digital travel platformAgoda has unveiled a list of destinations in Asia for each month of 2025,providing travelers with a month-by-month guide to the continent\'s seasonal a

Focus

Jan 13, 2025

Tuya Smart Hosts Successful 'Tuya Developer Day' During CES 2025, Leading Industry Change with Innovative AI Technology

LAS VEGAS,Jan. 10,2025-- Tuya Smart (NYSE: TUYA,HKEX: 2391),a global cloud platform service provider,successfully hosted its highly anticipated Tuya Developer Day event during CES 2025.

Focus

Jan 11, 2025

Tuya Smart Showcases Popular AI Innovations at CES 2025, Defining a New Standard for Future Smart Living

LAS VEGAS,Jan. 10,2025-- Tuya Smart (NYSE: TUYA,HKEX: 2391),a global cloud platform service provider,presented its cutting-edge innovations at CES 2025,which not only showcased numerous cutting-edge t

Focus

Jan 11, 2025

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

HANGZHOU,China,Jan. 10,2025--HangzhouSciwind Biosciences Co.,a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases,today announced a licens

Focus

Jan 11, 2025
1 ... 142 143 144 145 146